How lack of data may have cost a pharmaceutical giant billions
With 2015 sales of US$1.6Bn and 2017 projected sales of US$2Bn, Bristol-Myers Squibb’s (BMS’) anti-cancer drug dasatinib (Sprycel®) is highly successful and of great interest to competitors. A February 2017 decision from a Technical Board of Appeal at the EPO (European Patent Office) has resulted in the patent covering dasatinib being revoked. But why?
European patent 1169038  covering dasatinib was granted in 2012, opposed in 2013, revoked in January 2016, and the revocation upheld in an appeal deci